论文部分内容阅读
目的 :检测白血病患者WT1基因的表达水平 ,并探讨其与临床的关系。方法 :应用逆转录 聚合酶链反应(RT PCR)技术 ,检测 5 8例初治急性白血病 (AL)、2 0例慢性粒细胞白血病 (CML)和 10例非血液病患者WT1基因的表达。结果 :10例非血液病患者WT1基因的表达均呈阴性。 5 8例AL患者 44例检测有WT1基因的表达 ,阳性率为 75 .9% ,其中急性髓性白血病 (AML)阳性率为 86 .4% ,急性淋巴细胞白血病 (ALL)为 42 .9% ,两者差异有显著性 (P <0 .0 1) :AML治疗前WT1的表达水平与完全缓解 (CR)率无相关 (P >0 .0 5 ) ,但倾向于WT1基因低表达者有更高的CR率 (低表达组CR率为 75 .0 % ,高表达组率为 34 .8% )。CML慢性期WT1的表达水平极低 ,随临床分期进展水平增高 ,高表达者预示急变。结论 :AL和CML急变期患者WT1基因过度表达 ,初治AML治疗前WT1的表达水平与疗效无相关 ,但低表达组CR为 75 % ,高表达组CR为 34 .8%。
Objective: To detect the expression of WT1 gene in patients with leukemia and to explore its relationship with clinical. Methods: The expression of WT1 gene in 58 patients with newly diagnosed acute leukemia (AL), 20 chronic myeloid leukemia (CML) and 10 non-hematologic malignancies was detected by reverse transcription polymerase chain reaction (RT PCR). Results: The expression of WT1 gene in 10 non-hematological patients was negative. The expression of WT1 gene was detected in 44 of 58 patients with AL, the positive rate of which was 75.9%. The positive rate of AML was 86.4% and that of acute lymphoblastic leukemia was 42.9% (P <0.01). There was no correlation between the expression level of WT1 and the rate of complete remission (CR) before AML treatment (P> 0.05), but there was a tendency of low expression of WT1 gene Higher CR rate (low expression group CR rate of 75.0%, high expression group rate of 34.8%). The expression of WT1 in chronic phase of CML is extremely low, and as the clinical stage progresses, the expression of WT1 is higher than that of normal stage. CONCLUSIONS: WT1 gene is overexpressed in AL and CML patients. The expression level of WT1 in naive AML patients has no correlation with the efficacy, but the CR of low expression group is 75% and that of high expression group is 34.8%.